Catalyst Wire Dossier Catalyst Wire Dossier

TYRA-430

TYRA-430 · Tyra Biosciences, Inc
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TYRA-430, covering 2025-11-20 to 2025-11-20. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations [Phase 1]

See pricing